Prognostic value of myocardial perfusion scintigraphy in elderly patients with hypertension: a 10-year follow-up analysis

2012 ◽  
Vol 39 (10) ◽  
pp. 1570-1580 ◽  
Author(s):  
Luca Nai Fovino ◽  
Giorgio Saladini ◽  
Anna Rita Cervino ◽  
Francesca Saladini ◽  
Michele Gregianin ◽  
...  
Keyword(s):  
Myocardial Perfusion ◽  
Elderly Patients ◽  
Prognostic Value ◽  
Myocardial Perfusion Scintigraphy ◽  
Perfusion Scintigraphy

scholarly journals Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial

2021 ◽  
Author(s):  
Federico Caobelli ◽  
◽  
Philip Haaf ◽  
Gianluca Haenny ◽  
Matthias Pfisterer ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Myocardial Perfusion ◽  
Cardiovascular Events ◽  
Prognostic Value ◽  
Myocardial Perfusion Scintigraphy ◽  
Major Adverse Cardiovascular Events ◽  
Diabetic Patients ◽  
Perfusion Scintigraphy ◽  
High Cardiovascular Risk

Abstract Background The Basel Asymptomatic High-Risk Diabetics’ Outcome Trial (BARDOT) demonstrated that asymptomatic diabetic patients with an abnormal myocardial perfusion scintigraphy (MPS) were at increased risk of major adverse cardiovascular events (MACEs) at 2-year follow-up. It remains unclear whether this finding holds true even for a longer follow-up. Methods Four hundred patients with type 2 diabetes, neither history nor symptoms of coronary artery disease (CAD), were evaluated clinically and with MPS. Patients were followed up for 5 years. Major adverse cardiovascular events (MACEs) were defined as all-cause death, myocardial infarction, or late coronary revascularization. Results At baseline, an abnormal MPS (SSS ≥ 4 or SDS ≥ 2) was found in 87 of 400 patients (22%). MACE within 5 years occurred in 14 patients with abnormal MPS (16.1%) and in 22 with normal scan (1.7%), p = 0.009; 15 deaths were recorded. Patients with completely normal MPS (SSS and SDS = 0) had lower rates of MACEs than patients with abnormal scans (2.5% vs. 7.0%, p = 0.032). Patients with abnormal MPS who had undergone revascularization had a lower mortality rate and a better event-free survival from MI and revascularization than patients with abnormal MPS who had either undergone medical therapy only or could not be revascularized (p = 0.002). Conclusions MPS may have prognostic value in asymptomatic diabetic patients at high cardiovascular risk over a follow-up period of 5 years. Patients with completely normal MPS have a low event rate and may not need retesting within 5 years. Patients with an abnormal MPS have higher event rates and may benefit from a combined medical and revascularization approach.

The prognostic value of myocardial perfusion scintigraphy: investigators, are you (mis)leading us?

2001 ◽  
Vol 28 (9) ◽  
pp. 1299-1305
Author(s):  
Judocus J. J. Borm ◽  
Hanneke Bouwsma ◽  
Ernst E. van der Wall ◽  
Ernest K. J. Pauwels
Keyword(s):  
Myocardial Perfusion ◽  
Prognostic Value ◽  
Myocardial Perfusion Scintigraphy ◽  
Perfusion Scintigraphy

The prognostic value of myocardial perfusion scintigraphy: investigators, are you (mis)leading us?

2001 ◽  
Vol 28 (9) ◽  
pp. 1439-1446
Author(s):  
Judocus J. J. Borm ◽  
Hanneke Bouwsma ◽  
Ernst E. van der Wall ◽  
Ernest K. J. Pauwels
Keyword(s):  
Myocardial Perfusion ◽  
Prognostic Value ◽  
Myocardial Perfusion Scintigraphy ◽  
Perfusion Scintigraphy

Prognostic value of myocardial perfusion scintigraphy in diabetic patients and without coronary lesion

2021 ◽  
Vol 40 (2) ◽  
pp. 100-106
Author(s):  
E. López Rodríguez ◽  
B. Jauregui Garrido ◽  
J. Ruiz Franco-Baux ◽  
L. Caballero Gullón ◽  
A. Guisado Rasco ◽  
...  
Keyword(s):  
Myocardial Perfusion ◽  
Prognostic Value ◽  
Myocardial Perfusion Scintigraphy ◽  
Diabetic Patients ◽  
Perfusion Scintigraphy ◽  
Coronary Lesion

scholarly journals Assessment of the warranty period of a normal myocardial perfusion scintigraphy in patients with diabetes mellitus: 5 year follow-up of the prospective multicenter BARDOT trial

2021 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
P Haaf ◽  
F Caobelli ◽  
G Haenny ◽  
M Pfisterer ◽  
MJ Zellweger
Keyword(s):  
Myocardial Perfusion ◽  
Myocardial Perfusion Scintigraphy ◽  
Coronary Revascularization ◽  
Major Adverse Cardiovascular Events ◽  
Diabetic Patients ◽  
Cardiac Events ◽  
Perfusion Scintigraphy ◽  
Warranty Period ◽  
Increased Risk

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Swiss National Foundation for Research Background Asymptomatic diabetic patients with an abnormal myocardial perfusion scintigraphy (MPS) are known to be at an increased risk of major cardiac events (MACE) at 2-years follow-up. It remains unclear whether this finding holds true even for a follow-up of 5 years. Methods four hundred patients with type-2 diabetes without coronary artery disease were evaluated clinically and with MPS and followed up for 5 years. Major adverse cardiovascular events (MACE) were defined as cardiac death, myocardial infarction or late coronary revascularization.  Results  An abnormal MPS (SSS≥4 or SSS≥2) was found in 87 patients (21.8%). MACE within 5 years occurred in 14 patients with abnormal MPS (16.1%) and in 22 with normal scan (1.7%, p = 0.009); 15 deaths were recorded (3.8%). Patients with normal MPS had lower rates of MACEs than patients with abnormal scans (p = 0.016) (Figure 1A + B). Patients with abnormal MPS who had undergone revascularization had a lower mortality rate and a better event free survival from MI and revascularization than patients with abnormal MPS who had either undergone medical therapy only or could not be revascularized (Figure 1C + D).  Conclusions Patients with  normal MPS have a low event rate and may not need retesting within 5 years (warranty period). Patients with an abnormal MPS have higher event rates and may benefit from a combined medical and revascularization approach. Abstract Figure 1 A-D

Sign in / Sign up

Export Citation Format

Share Document